Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on extracellular vesicles, including exosomes and other nanotechnologies.
Exo-101, derived from immunologically privileged cells from umbilical cord blood, has been shown to have regenerative, anti‑inflammatory, and immunomodulatory properties in multiple preclinical models and is expected to reach patients in 2027, according to an Exogenus spokesperson, who added that its multifactorial mode-of-action, mediated by a cocktail of small RNAs, proteins and anti-inflammatory lipids, provides the foundation for the drug’s therapeutic potential and positive safety profile.
Tissue regeneration and inflammatory disease
Exo-101 targets patients lacking effective treatment options primarily in the areas of tissue regeneration and inflammatory diseases. Lonza will leverage its expertise in exosome development and analytical services from its Siena (IT) site and dedicate a team of experts to define a GMP-compliant process for Exo-101 production. This feasibility effort aims to define the path toward Exo-101 manufacturing for clinical supply.
“We are committed to developing innovative, safe, and effective therapies in areas of high unmet medical needs, and to establishing new uses for biological waste materials,” said Joana Correia, co-founder and CEO, Exogenus Therapeutics. “This collaboration with Lonza will be essential to achieve a robust, GMP-compliant process for Exo-101 manufacturing, as we progress toward clinical studies.”
”We continue to pioneer this emerging and promising field of exosomes, leading innovation to provide development and manufacturing services for our partners,” added Davide Zocco, head of exosomes development at Lonza. We look forward to collaborating with Exogenus Therapeutics to advance its lead candidate toward the clinic.”